Advertisement
Advertisement
U.S. Markets open in 40 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sana Biotechnology, Inc. (SANA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.25+0.27 (+4.52%)
At close: 04:00PM EDT
6.06 -0.19 (-3.04%)
After hours: 04:08PM EDT
Advertisement

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98102
United States
206 701 7914
https://www.sana.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees420

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven D. Harr M.D.Pres, CEO & Director1.19MN/A1970
Dr. Richard C. Mulligan Ph.D.Exec. Vice Chairman & Head of SanaXN/AN/A1955
Mr. Nathan Hardy M.B.A.Exec. VP & CFO683.49kN/A1976
Dr. Sunil Agarwal M.D.Exec. VP, Head of Devel. & Chief Medical Officer728.45kN/A1970
Ms. Shanna Clouse PeekSr. VP & Head of Corp. OperationsN/AN/AN/A
Brittany MccleeryAccounting Mang.N/AN/AN/A
Dr. Edward Rebar Ph.D.Sr. VP & CTON/AN/A1968
Mr. James J. MacDonald J.D.Exec. VP, Gen. Counsel & Sec.N/AN/A1975
Ms. Robin AndrulevichExec. VP & Chief People OfficerN/AN/A1966
Mr. Paul Brunetta M.D.Sr. VP and Head of Clinical & Translational ScienceN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Corporate Governance

Sana Biotechnology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement